Rhes suppression enhances disease phenotypes in Huntington's disease mice

Journal of Huntington's Disease

Volumn 3, Issue 1, 2014, Pages 65-71

  Lee, John H ^a   Sowada, Matthew J ^a   Boudreau, Ryan L ^a   Aerts, Andrea M ^a   Thedens, Daniel R ^a   Nopoulos, Peg ^a   Davidson, Beverly L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

genetic therapies; Huntington disease; neurodegenerative disease; rasd2; Rhes; RNA interference

Indexed keywords

RHEB PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; CORPUS STRIATUM; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUMOYLATION;

GENETIC THERAPIES; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASE; RASD2; RHES; RNA INTERFERENCE;

ANIMALS; ANXIETY; ATROPHY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GTP-BINDING PROTEINS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MICRORNAS; MUTANT PROTEINS; NEOSTRIATUM; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHENOTYPE;

EID: 84908116685     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140094     Document Type: Article

References (28)

1. Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72:971-83.
2. Spano D, Branchi I, Rosica A, Pirro MT, Riccio A, Mithbaokar P, Affuso A, Arra C, Campolongo P, Terracciano D, Macchia V, Bernal J, Alleva E, Di Lauro R. Rhes is involved in striatal function. Mol Cell Biol. 2004;24:5788-96. (Pubitemid 38787964)
3. Quintero GC, Spano D, Lahoste GJ, Harrison LM. The Ras homolog Rhes affects dopamine D1 and D2 receptormediated behavior in mice. Neuroreport. 2008;19:1563-6.
4. Subramaniam S, Mealer RG, Sixt KM, Barrow RK, Usiello A, Snyder SH. Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9. J Biol Chem. 2010;285:20428-32.
5. Vargiu P, Morte B, Manzano J, Perez J, de Abajo R, Gregor Sutcliffe J, Bernal J. Thyroid hormone regulation of rhes, a novel Ras homolog gene expressed in the striatum. Brain Res Mol Brain Res. 2001;94:1-8. (Pubitemid 32964740)
6. Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, Barrow R, Shahani N, Tyagi R, Snyder SH, Usiello A. Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci. 2012;15:191-3.
7. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-93.
8. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science. 2009;324:1327-30.
9. Lu B, Palacino J. A novel human embryonic stem cellderived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 2013;27:1820-9.
10. Seredenina T, Gokce O, Luthi-Carter R. Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS One. 2011;6:e22231.
11. Mealer RG, Subramaniam S, Snyder SH. Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease. J Neurosci. 2013;33:4206-4210.
12. Baiamonte BA, Lee FA, Brewer ST, Spano D, LaHoste GJ. Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease. PLoS One. 2013;8:e53606.
13. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008;105:5868-73. (Pubitemid 351758464)
14. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999;8:397-407. (Pubitemid 29097327)
15. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28:6182-95.
16. Cheng Y, Peng Q, Hou Z, Aggarwal M, Zhang J, Mori S, Ross CA, Duan W. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage. 2011;56:1027-34.
17. Mealer RG, Murray AJ, Shahani N, Subramaniam S, Snyder SH. Rhes, a Striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. J Biol Chem. 2013
18. Ravikumar B,Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585-95. (Pubitemid 38715985)
19. Yamamoto A, Cremona ML, Rothman JE. Autophagymediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol. 2006;172:719-31.
20. Choi BR, Bang S, Chen Y, Cheah JH, Kim SF. PKA modulates iron trafficking in the striatum via small GTPase, Rhes. Neuroscience. 2013;253:214-20.
21. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RL, Olson JM, Jones L, Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006;15:965-77. (Pubitemid 43338237)
22. Steffan JS. Does Huntingtin play a role in selective macroautophagy? Cell Cycle. 2010;9:3401-13.
23. Karassek S, Berghaus C, Schwarten M, Goemans CG, Ohse N, Kock G, Jockers K, Neumann S, Gottfried S, Herrmann C, Heumann R, Stoll R. Ras homolog enriched in brain (Rheb) enhances apoptotic signaling. J Biol Chem. 2010;285:33979- 91.
24. Zuchner T, Brundin P. Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ. 2008;15:435- 42. (Pubitemid 351267294)
25. Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: Minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther. 2011;19:2169-77.
26. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009;17:1053-63.
27. Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis. 2009;35:319-36.
28. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102:5820-5. (Pubitemid 40559643)